title: Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures.
abstract: Daidzein, a major isoflavone predominantly found in soybean, is mainly metabolized to equol and O-desmethylangolensin (O-DMA) by the human gut microflora. Equol exhibits a stronger estrogenic activity than daidzein, however, only approximately 30% of the population has been identified as equol-producers and there are too few direct evidences of the effects of the other major metabolite, O-DMA on estrogen-deficient status. The purpose of this study is therefore, to compare the effect of both O-DMA and equol on bone and lipid metabolism in vivo and in vitro. For the in vivo study, 8-week-old female mice were assigned to five groups as follows: sham-operated (sham), ovariectomized (OVX), OVX + 0.5 mg/day O-DMA (OVX + O-DMA), OVX + 0.5 mg/day equol (OVX + Eq), and OVX + 0.03 microg/day 17beta-estradiol (OVX + E2) administration. Three weeks after the intervention, O-DMA and equol did not affect uterine atrophy in OVX mice. The bone mineral density (BMD) of the femur was lower in the OVX group than in the sham group. The administration of equol but not O-DMA, maintained BMD through the intervention. Values of whole body fat mass and plasma lipids were lower in the equol and O-DMA treated OVX mice than those in OVX mice. In the in vitro study, equol significantly inhibited the osteoclast formation induced by 1alpha,25(OH)(2)D(3) in a dose-dependent manner in a co-culture system of mouse bone-marrow cells with primary osteoblastic cells. However, O-DMA slightly inhibited osteoclast formation, and the effect was not dose dependent. These results suggest that the effects of O-DMA on bone and lipid metabolism in OVX mice and osteoclast cell cultures are weaker than those of equol.
authors.affiliation: Project for Bio-index, Nutritional Epidemiology Program, National Institute of Health and Nutrition, Toyama, Tokyo, Japan.
authors.forename: Takuya
authors.initials: T
authors.lastname: Ohtomo
authors.forename: Mariko
authors.initials: M
authors.lastname: Uehara
authors.forename: José Luis
authors.initials: JL
authors.lastname: Peñalvo
authors.forename: Herman
authors.initials: H
authors.lastname: Adlercreutz
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Katsumata
authors.forename: Kazuharu
authors.initials: K
authors.lastname: Suzuki
authors.forename: Ken
authors.initials: K
authors.lastname: Takeda
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Masuyama
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Ishimi
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D018920:Coculture Techniques; D004305:Dose-Response Relationship, Drug; D060754:Equol; D004968:Estrogens, Non-Steroidal / Q000494:pharmacology*; D005260:Female; D007529:Isoflavones / Q000378:metabolism / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects* / Q000502:physiology; D051379:Mice; D008815:Mice, Inbred Strains; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism; D010024:Osteoporosis / Q000517:prevention & control; D010052:Ovariectomy; D011897:Random Allocation
chemical_list: C007610:4',7-dihydroxy-3,4-dihydroisoflavone; D004968:Estrogens, Non-Steroidal; D007529:Isoflavones; D060754:Equol; C004742:daidzein; C050052:O-desmethylangolensin